Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300064 | 0.93 | NOTUM (0.51) | NOTUMMKNK2MKNK1PIK3CDPIK3CB | |
| SCHEMBL30518383 | 0.93 | NOTUM (0.51) | NOTUMMKNK2MKNK1PIK3CDPIK3CB | |
| Bicarbonate SCHEMBL28453614 | 0.84 | NPC1 (0.40) | NOTUMMKNK2MKNK1NAPRTHPGD | |
| SCHEMBL30518381 | 0.81 | L3MBTL1 (0.43) | NOTUMMKNK2MKNK1PIK3CDPIK3CB | |
| SCHEMBL21054794 | 0.81 | L3MBTL1 (0.43) | NOTUMMKNK2MKNK1PIK3CDPIK3CB | |
| SCHEMBL2302221 | 0.81 | MAPT (0.46) | MKNK2MKNK1NAPRTHPGDNPC1 | |
| SCHEMBL2304162 | 0.79 | MAP4K4 (0.41) | NOTUMMKNK2MKNK1HPGDNPC1 | |
| SCHEMBL12369663 | 0.79 | PIK3CD (0.41) | NOTUMMKNK2MKNK1PIK3CDPIK3CB | |
| SCHEMBL29043732 | 0.78 | L3MBTL1 (0.57) | NOTUMMKNK2NPC1ALDH1A1CYP1A2 | |
| SCHEMBL3398933 | 0.78 | NOTUM (0.48) | NOTUMHPGDNPC1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223926-B1 | PYRIDINE DERIVATIVE SUBSTITUTED WITH HETEROCYCLE AND PHOSPHONOXYMETHYL GROUP AND ANTIFUNGAL AGENT CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8513287-B2 | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8410277-B2 | Method for manufacturing heterocycle substituted pyridine derivatives | Eisai R&D Managment Co., Ltd. (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120277439-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND y-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | TANAKA KEIGO (JP) | 2012-11-01 | — | — | US | disclosed |
| US-8188119-B2 | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same | EISAI R&D MANAGEMENT CO., LTD (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20110263845-A1 | METHOD FOR MANUFACTURING HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2351752-A1 | PYRIDINE DERIVATIVE HAVING SUBSTITUTED HETERO RING AND SUBSTITUTED y-GLUTAMYLAMINO GROUP, AND ANTI-FUNGAL AGENT COMPRISING SAME | Eisai R&D Management Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2226320-A1 | PROCESS FOR PRODUCTION OF HETEROCYCLE-SUBSTITUTED PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2223926-A1 | PYRIDINE DERIVATIVE SUBSTITUTED WITH HETEROCYCLE AND PHOSPHONOXYMETHYL GROUP AND ANTIFUNGAL AGENT CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20100105737-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20090233883-A1 | HETEROCYCLIC RING AND PHOSPHONOXYMETHYL GROUP SUBSTITUTED PYRIDINE DERIVATIVES AND ANTIFUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105737-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | ASNS, ERG28, GLUL | NOTUM 3916/4885MKNK2 3897/4885MKNK1 3526/4885 |
| US-20120277439-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND y-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | ASNS, GLUL, IL4I1 | NOTUM 4065/4885MKNK2 2921/4885MKNK1 3366/4885 |
| US-20090233883-A1 | HETEROCYCLIC RING AND PHOSPHONOXYMETHYL GROUP SUBSTITUTED PYRIDINE DERIVATIVES AND ANTIFUNGAL AGENT CONTAINING SAME | MTOR, ERG28, MTMR1 | NOTUM 2119/4885MKNK2 263/4885MKNK1 127/4885 |
| US-20110263845-A1 | METHOD FOR MANUFACTURING HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVES | CBR3, NQO1, F12 | NOTUM 3060/4885MKNK2 2941/4885MKNK1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.